ADMA Biologics (NASDAQ:ADMA) saw its stock price plummet by 17.72% in pre-market trading on Thursday, following a disappointing after-hours session on Wednesday. The sharp decline comes in the wake of the company's second-quarter financial results release, which revealed mixed performance metrics that fell short of investor expectations.

While ADMA Biologics met earnings expectations with $0.14 per share, representing a 7.69% year-over-year increase, the company's quarterly sales failed to impress. ADMA reported revenue of $121.98 million, missing the consensus forecast of $122.67 million by 0.56%. Despite this figure still representing a 13.80% increase compared to the same period last year, the sales miss appears to have triggered significant investor concern.

The market's severe reaction highlights the high expectations placed on growth-oriented companies in the biotech sector. Even a slight miss in revenue projections can lead to substantial stock price movements, as evidenced by ADMA Biologics' pre-market plunge. This downturn follows an already significant after-hours drop of over 10% on Wednesday, indicating that investors are rapidly reassessing their positions and expectations for the biopharmaceutical company in light of the latest financial results.